rs113993959
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs74597325
|
|
T |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
rs77010898
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Cystic fibrosis (CF) patients bearing the premature translation termination mutation (nonsense mutation) W1282X present severe pulmonary and pancreatic disease, whereas patients carrying other nonsense mutations such as G542X, R553X, S1255X, R1162X, and W1316X show a severe pancreatic but mild pulmonary illness.
|
7504691 |
1993 |
rs17107315
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In Bangladesh, the SPINK1 N34S mutation increases the risk of several forms of pancreatic disease, including fibrocalculous pancreatic diabetes, tropical calcific pancreatitis, and non-insulin-dependent diabetes mellitus.
|
12360464 |
2002 |
rs1799945
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Heterozygosity of p.C282Y and p.H63D may increase susceptibility to chronic liver and pancreatic disease.
|
17666895 |
2007 |
rs1800562
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Heterozygosity of p.C282Y and p.H63D may increase susceptibility to chronic liver and pancreatic disease.
|
17666895 |
2007 |
rs1051740
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The role of epoxide hydrolase Y113H gene variant in pancreatic diseases.
|
19287329 |
2009 |
rs10094872
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This analysis, in combination with a two-staged replication in an additional 6,076 case and 7,555 control subjects from the PANcreatic Disease ReseArch (PANDoRA) and Pancreatic Cancer Case-Control (PanC4) Consortia uncovered 3 new pancreatic cancer risk signals marked by single nucleotide polymorphisms (SNPs) rs2816938 at chromosome 1q32.1 (per allele odds ratio (OR) = 1.20, P = 4.88x10 -15), rs10094872 at 8q24.21 (OR = 1.15, P = 3.22x10 -9) and rs35226131 at 5p15.33 (OR = 0.71, P = 1.70x10 -8).
|
27579533 |
2016 |
rs2816938
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This analysis, in combination with a two-staged replication in an additional 6,076 case and 7,555 control subjects from the PANcreatic Disease ReseArch (PANDoRA) and Pancreatic Cancer Case-Control (PanC4) Consortia uncovered 3 new pancreatic cancer risk signals marked by single nucleotide polymorphisms (SNPs) rs2816938 at chromosome 1q32.1 (per allele odds ratio (OR) = 1.20, P = 4.88x10 -15), rs10094872 at 8q24.21 (OR = 1.15, P = 3.22x10 -9) and rs35226131 at 5p15.33 (OR = 0.71, P = 1.70x10 -8).
|
27579533 |
2016 |
rs35226131
|
|
|
0.010 |
GeneticVariation |
BEFREE |
This analysis, in combination with a two-staged replication in an additional 6,076 case and 7,555 control subjects from the PANcreatic Disease ReseArch (PANDoRA) and Pancreatic Cancer Case-Control (PanC4) Consortia uncovered 3 new pancreatic cancer risk signals marked by single nucleotide polymorphisms (SNPs) rs2816938 at chromosome 1q32.1 (per allele odds ratio (OR) = 1.20, P = 4.88x10 -15), rs10094872 at 8q24.21 (OR = 1.15, P = 3.22x10 -9) and rs35226131 at 5p15.33 (OR = 0.71, P = 1.70x10 -8).
|
27579533 |
2016 |
rs1800629
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We genotyped the selected SNPs (rs16944, rs1052536, rs1059293, rs1136410, rs1143634, rs2069762, rs2236302, rs2387632, rs3212961, rs3734299, rs3803258, rs4962081, rs7234941, rs7243091, rs12957119, and rs1800629) in 344 PNET sporadic cases and 2,721 controls in the context of the PANcreatic Disease ReseArch (PANDoRA) consortium.<b>Results:</b> After correction for multiple testing, we did not observe any statistically significant association between the SNPs and PNET risk.
|
28765340 |
2017 |